Luke Kish
5.4K posts

Luke Kish
@LukeKish
Think With Me ⚡️Multi 8figure CEO @warriorbabe 🙋♂️Follow & you’ll begin to see your visions are possible
Se unió Mart 2011
201 Siguiendo5.2K Seguidores

I’ve been trying so hard to control
Outcomes, what I think, how I feel.
Yet - the best things in my life have come completely unplanned without me looking
It is so hard for everyone including me to let go and let happen.
I’ve been trying to force outcomes for 12 years after an intense period of pain.
And only now am realizing how much this loop has affected my whole life since then.
Control comes from ourselves, keeping other parts of ourselves, safe.
From the emotions we don’t want to feel, and the things in us that need worked through.
But it’s all an illusion.
What we think we are getting through control further pushes away our having it.
Control is saving us from the parts of ourselves that if we humbly confront.
Open us and expand us for more blessings.
English

yesterday we vibecoded a webinar dashboard
1 shot prompt
take a look
the amount of traction I’ve seen building around AI over the last 48 hours is insane
we are still super early in this new wave and there is so much to learn
i want to know the amazing systems you guys are building to implement within your businesses
i feel like entrepreneurship is about to see a crazy shift with not only productivity bandwidth but also brand growth and fulfilment too
English

I’d cancel your AG1 subscription. They just completed a clinical trial and the results show no clinical benefit.
This has been obvious for years. AG1 has no real product substance and is fundamentally an influencer heist.
Two simple alternatives (75% and 56% less $), outperform AG1 in randomized clinical trials.
Two simple mono-ingredient alternatives that outperform AG1:
1. Chicory inulin 12 g daily ($20/mo)
2. Resistant starch 30 g daily for 12 weeks ($35/mo)
AG1 is not worth $79/mo.
AG1 study results (4-weeks, N=30):
+ No significant changes in blood biomarkers compared to placebo (CBC, CMP, lipids).
+ No statistically significant improvement in digestive quality-of-life scores (p = 0.058).
+ No significant metabolic or inflammatory biomarker benefits of any kind within the scope of what was measured in the trial.
+ Only small shifts in microbiome taxa but clinically irrelevant at this stage.
+ The intervention did not increase microbiome diversity compared to placebo. Alpha diversity was unchanged, and the taxa changes seen were only from pre- to post-analysis within each group. Between-group differences were limited, and the placebo actually showed similar or even potentially larger shifts. This means the observed changes fall within normal placebo-driven variability, not a real treatment effect. No global microbiota shifts were detected.
Chicory inulin 12 g in constipation patients
+ 12 g of chicory inulin daily for 4 weeks (compared to maltodextrin placebo)
+ Global microbiota shifts: enrichment in butyrate-producing Bifidobacterium and Anaerostipes, and depletion of the pro-inflammatory Bilophila.
+The effect was seen by comparing intervention vs placebo in a cross-over setting, a very rigorous type of clinical analysis in which each person serves as their own control, eliminating a lot of individual random noise.
+ The trial also met its primary objective by improving constipation symptoms in the targeted patient group.
Resistant starch daily 30g for 12 weeks in older adults
+ Significant increase in Bifidobacterium in both middle-aged and elderly participants, with an increase in the beneficial microbiome byproduct butyrate, and reductions in Proteobacteria (including inflammatory Escherichia–Shigella) in the elderly.
+ Resistant starch also significantly reduced blood glucose, and produced greater reductions in blood insulin and insulin resistance (HOMA-IR) in the elderly group.

English

